Header Logo

Connection

Susan Hogan to Immunosuppressive Agents

This is a "connection" page, showing publications Susan Hogan has written about Immunosuppressive Agents.
Connection Strength

2.286
  1. McGregor JG, Negrete-Lopez R, Poulton CJ, Kidd JM, Katsanos SL, Goetz L, Hu Y, Nachman PH, Falk RJ, Hogan SL. Adverse events and infectious burden, microbes and temporal outline from immunosuppressive therapy in antineutrophil cytoplasmic antibody-associated vasculitis with native renal function. Nephrol Dial Transplant. 2015 Apr; 30 Suppl 1:i171-81.
    View in: PubMed
    Score: 0.423
  2. Geetha D, Poulton CJ, Hu Y, Seo P, McGregor JA, Falk RJ, Hogan SL. Clinical characteristics and outcome of pauci-immune glomerulonephritis in African Americans. Semin Arthritis Rheum. 2014 Jun; 43(6):778-83.
    View in: PubMed
    Score: 0.386
  3. Hogan SL, Falk RJ, Chin H, Cai J, Jennette CE, Jennette JC, Nachman PH. Predictors of relapse and treatment resistance in antineutrophil cytoplasmic antibody-associated small-vessel vasculitis. Ann Intern Med. 2005 Nov 01; 143(9):621-31.
    View in: PubMed
    Score: 0.220
  4. Massicotte-Azarniouch D, Detwiler RK, Hu Y, Falk RJ, Saha MK, van Duin D, Hogan SL, Derebail VK. Infections Following Kidney Transplantation After Exposure to Immunosuppression for Treatment of Glomerulonephritis. Am J Kidney Dis. 2024 06; 83(6):784-793.e1.
    View in: PubMed
    Score: 0.194
  5. Laurin LP, Gasim AM, Derebail VK, McGregor JG, Kidd JM, Hogan SL, Poulton CJ, Detwiler RK, Jennette JC, Falk RJ, Nachman PH. Renal Survival in Patients with Collapsing Compared with Not Otherwise Specified FSGS. Clin J Am Soc Nephrol. 2016 10 07; 11(10):1752-1759.
    View in: PubMed
    Score: 0.116
  6. Rhee RL, Hogan SL, Poulton CJ, McGregor JA, Landis JR, Falk RJ, Merkel PA. Trends in Long-Term Outcomes Among Patients With Antineutrophil Cytoplasmic Antibody-Associated Vasculitis With Renal Disease. Arthritis Rheumatol. 2016 07; 68(7):1711-20.
    View in: PubMed
    Score: 0.115
  7. Laurin LP, Gasim AM, Poulton CJ, Hogan SL, Jennette JC, Falk RJ, Foster BJ, Nachman PH. Treatment with Glucocorticoids or Calcineurin Inhibitors in Primary FSGS. Clin J Am Soc Nephrol. 2016 Mar 07; 11(3):386-94.
    View in: PubMed
    Score: 0.112
  8. McGregor JG, Hogan SL, Kotzen ES, Poulton CJ, Hu Y, Negrete-Lopez R, Kidd JM, Katsanos SL, Bunch DO, Nachman PH, Falk RJ. Rituximab as an immunosuppressant in antineutrophil cytoplasmic antibody-associated vasculitis. Nephrol Dial Transplant. 2015 Apr; 30 Suppl 1:i123-31.
    View in: PubMed
    Score: 0.106
  9. Lee T, Gasim A, Derebail VK, Chung Y, McGregor JG, Lionaki S, Poulton CJ, Hogan SL, Jennette JC, Falk RJ, Nachman PH. Predictors of treatment outcomes in ANCA-associated vasculitis with severe kidney failure. Clin J Am Soc Nephrol. 2014 May; 9(5):905-13.
    View in: PubMed
    Score: 0.098
  10. Bunch DO, McGregor JG, Khandoobhai NB, Aybar LT, Burkart ME, Hu Y, Hogan SL, Poulton CJ, Berg EA, Falk RJ, Nachman PH. Decreased CD5? B cells in active ANCA vasculitis and relapse after rituximab. Clin J Am Soc Nephrol. 2013 Mar; 8(3):382-91.
    View in: PubMed
    Score: 0.091
  11. McGregor JG, Hogan SL, Hu Y, Jennette CE, Falk RJ, Nachman PH. Glucocorticoids and relapse and infection rates in anti-neutrophil cytoplasmic antibody disease. Clin J Am Soc Nephrol. 2012 Feb; 7(2):240-7.
    View in: PubMed
    Score: 0.084
  12. Pagnoux C, Hogan SL, Chin H, Jennette JC, Falk RJ, Guillevin L, Nachman PH. Predictors of treatment resistance and relapse in antineutrophil cytoplasmic antibody-associated small-vessel vasculitis: comparison of two independent cohorts. Arthritis Rheum. 2008 Sep; 58(9):2908-18.
    View in: PubMed
    Score: 0.067
  13. Hogan SL, Falk RJ, Nachman PH, Jennette JC. Various forms of life in antineutrophil cytoplasmic antibody-associated vasculitis. Ann Intern Med. 2006 Mar 07; 144(5):377-8; author reply 378-9.
    View in: PubMed
    Score: 0.056
  14. Joy MS, Hogan SL, Jennette JC, Falk RJ, Nachman PH. A pilot study using mycophenolate mofetil in relapsing or resistant ANCA small vessel vasculitis. Nephrol Dial Transplant. 2005 Dec; 20(12):2725-32.
    View in: PubMed
    Score: 0.055
  15. Joy MS, Nickeleit V, Hogan SL, Thompson BD, Finn WF. Calcineurin inhibitor-induced nephrotoxicity and renal expression of P-glycoprotein. Pharmacotherapy. 2005 Jun; 25(6):779-89.
    View in: PubMed
    Score: 0.054
  16. Cao B, Robinson JE, Winget M, Hunt MH, Carlson R, Hogan SL, Derebail VK, Thorpe CT. Infection prophylaxis among patients with antineutrophil cytoplasmic antibody (ANCA) vasculitis: a scoping review. Clin Rheumatol. 2024 Sep; 43(9):2765-2781.
    View in: PubMed
    Score: 0.050
  17. Franceschini N, Hogan SL, Falk RJ. Primum non nocere: Should adults with idiopathic FSGS receive steroids? Semin Nephrol. 2003 Mar; 23(2):229-33.
    View in: PubMed
    Score: 0.046
  18. Klemmer PJ, Chalermskulrat W, Reif MS, Hogan SL, Henke DC, Falk RJ. Plasmapheresis therapy for diffuse alveolar hemorrhage in patients with small-vessel vasculitis. Am J Kidney Dis. 2003 Dec; 42(6):1149-53.
    View in: PubMed
    Score: 0.012
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.